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Abstract
Background: Although dendritic cell (DC) vaccines are considered to be promising treatments for advanced
cancer, their production and administration is costly and labor-intensive. We developed a novel immunotherapeutic
agent that links a single-chain antibody variable fragment (scFv) targeting mesothelin (MSLN), which is overex-
pressed on ovarian cancer and mesothelioma cells, to Mycobacterium tuberculosis (MTB) heat shock protein 70
(Hsp70), which is a potent immune activator that stimulates monocytes and DCs, enhances DC aggregation and
maturation and improves cross-priming of T cells mediated by DCs.
Methods: Binding of this fusion protein with MSLN on the surface of tumor cells was measured by flow cytometry
and fluorescence microscopy. The therapeutic efficacy of this fusion protein was evaluated in syngeneic and
orthotopic mouse models of papillary ovarian cancer and malignant mesothelioma. Mice received 4 intraperitoneal
(i.p.) treatments with experimental or control proteins post i.p. injection of tumor cells. Ascites-free and overall sur-
vival time was measured. For the investigation of anti-tumor T-cell responses, a time-matched study was performed.
Splenocytes were stimulated with peptides, and IFNγ- or Granzyme B- generating CD3
+CD8
+ T cells were detected
by flow cytometry. To examine the role of CD8
+ T cells in the antitumor effect, we performed in vivo CD8
+ cell
depletion. We further determined if the fusion protein increases DC maturation and improves antigen presentation
as well as cross-presentation by DCs.
Results: We demonstrated in vitro that the scFvMTBHsp70 fusion protein bound to the tumor cells used in this
study through the interaction of scFv with MSLN on the surface of these cells, and induced maturation of bone
marrow-derived DCs. Use of this bifunctional fusion protein in both mouse models significantly enhanced survival
and slowed tumor growth while augmenting tumor-specific CD8
+ T-cell dependent immune responses. We also
demonstrated in vitro and in vivo that the fusion protein enhanced antigen presentation and cross-presentation by
targeting tumor antigens towards DCs.
(Continued on next page)
* Correspondence: mpoznansky@partners.org
1Vaccine and Immunotherapy Center, Division of Infectious Diseases,
Department of Medicine, Massachusetts General Hospital, 149 13th Street,
Charlestown, Boston, MA 02129, USA
Full list of author information is available at the end of the article
JOURNAL OF HEMATOLOGY
& ONCOLOGY
© 2014 Yuan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Yuan et al. Journal of Hematology & Oncology 2014, 7:15
http://www.jhoonline.org/content/7/1/15(Continued from previous page)
Conclusions: This new cancer immunotherapy has the potential to be cost-effective and broadly applicable to
tumors that overexpress mesothelin.
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Background
The goal of cancer immunotherapy is to stimulate the
immune system to destroy cancer cells. Numerous strat-
egies that involve tumor antigen-specific and non-
specific activation of the immune system have been
developed. These include dendritic cell (DC) vaccines,
adoptive T-cell therapy and immune checkpoint block-
ade [1-3]. Antigen-specific active immunotherapy is ex-
pected to be the most attractive strategy because of its
capacity to induce both therapeutic and protective T-cell
immunity. Among various approaches, DC vaccine is
considered to be a promising treatment for advanced
cancer, based on the ability of DCs to orchestrate all of
the elements of the immune system. DCs capture tumor
antigens, process these antigens into peptides as they
move to the draining secondary lymphoid organs, and
present the peptides to naïve T cells, thus inducing anti-
tumor cellular immune responses. DCs can also activate
B cells, NK cells, and NKT cells [1]. In pre-clinical and
clinical studies that exploited DCs as a means to im-
prove vaccine efficiency, autologous DCs are loaded
ex vivo with antigens and re-administered to the patient.
For example, Sipuleucel-T (Provenge) that consists of
ex vivo activated autologous peripheral blood mono-
nuclear cells (PBMCs) including antigen-presenting cells
(APCs), has resulted in a significant survival benefit in
Phase III trials for prostate cancer [4]. However, the pro-
duction and administration of these tailor-made DC vac-
cines are costly and labor-intensive [5].
As a next-step in the development of DC vaccines, we
designed a recombinant protein that contains a Mycobac-
terium tuberculosis heat shock protein 70 (MTBHsp70)
fused to a single chain variable fragment (scFv) derived
from human B cells that targets mesothelin. Mesothelin
(MSLN) is a validated immunotherapy target that is highly
overexpressed on the surface of common epithelial can-
cers including ovarian cancers, epithelial malignant meso-
theliomas, ductal pancreatic adenocarcinomas, and lung
adenocarcinomas, while expressed at relatively low levels
only in mesothelial cells lining the pleura, pericardium,
and peritoneum in healthy individuals [6-9]. Several thera-
peutic agents targeting MSLN are evaluated in preclinical
and clinical studies such as the recombinant immunotoxin
SS1P [9-11]. In our fusion protein, the anti-MSLN scFv
moiety was originally isolated from a yeast-display human
scFv library [12] and demonstrated the ability to recognize
both membrane-bound and soluble MSLNs and inhibit
CA125/MSLN-dependent cell adhesion [13-15]. The re-
combinant MTBHsp70 protein provides immunostimula-
tory functions including the activation of monocytes and
DCs to produce CC-chemokines that attract antigen pro-
cessing and presenting DCs, macrophages, and effector T
and B cells, enhanced DC aggregation and maturation
[16,17], induction of the cytotoxic activity of natural killer
cells [18], and improved cross-priming of T cells which is
dependent on DCs [19]. The capabilities of MTBHsp70 as
a potent immune adjuvant have been well characterized in
cancer models including murine models of melanoma and
lymphoma [18,20-24]. While in these studies, proteins or
peptides fused with Hsp70 used for immunizations in
mice were shown to generate humoral or cellular immune
responses, we expect that fusion of anti-MSLN scFv and
MTBHsp70 takes advantage of the immune-activating ac-
tion of MTBHsp70 and the tumor-targeting activity of the
scFv, which will yield anti-tumor responses against the
broadest profile of tumor antigens.
We evaluated the therapeutic efficacy of this MSLN-
targeted fusion protein in syngeneic mouse models of
ovarian cancer and mesothelioma and examined its
mechanism of action in in vitro and in vivo cross-
presentation assay systems. These studies demonstrate
that this bifunctional fusion protein significantly en-
hances survival and slows tumor growth through the
augmentation of tumor-specific cell-mediated immune
responses.
Results
Expression of scFvMTBHsp70 fusion protein and
MTBHsp70
The structure of scFvMTBHsp70 is shown in Figure 1A.
VH and VL from anti-MSLN P4 scFv [13] are linked using
a (G4S)3 linker and fused to full length MTBHsp70 with
a (G4S)3 linker in between. As shown in Figure 1B,
only one protein band was observed with a molecular
weight of approximately 100 kDa for scFvMTBHsp70,
and one protein band with a molecular weight of
70 kDa for MTBHsp70, which match the expected
molecular weights of these specific proteins. Endo-
toxin contamination levels in scFvMTBHsp70 and
MTBHsp70 were found to be very low, at less than
50 EU per mg of protein.
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http://www.jhoonline.org/content/7/1/15Figure 1 Structure and analysis of scFvMTBHsp70 fusion protein. A, anti-MSLN VH and VL are linked with a (G4S)3 linker and fused to full
length MTBHsp70 with a (G4S)3 linker. B, RAPIDstain based on Coomassie dye following purification and hIgG-Fc tag removal of MTBHsp70
and scFvMTBHsp70. C, BR5FVB1 ovarian cancer cells and 40L mesothelioma cells were incubated with 40 μg/ml scFvMTBHsp70 or 26 μg/ml
MTBHsp70 (blue line), or without either protein (solid), followed by anti-MTBHsp70 (IgG2a), biotinylated anti-IgG2a, and Streptavidin-APC, and then
analyzed by flow cytometry. To confirm that the scFv portion of the fusion protein binds to MSLN on the surface of tumor cells, scFvMTBHsp70
or MTBHsp70 was preincubated with 12 μg/ml recombinant human MSLN for 30 min (red line) before being added to the cells. Data are repre-
sentative of three independent experiments in duplicate tubes. D, Median fluorescence intensity (MFI) values of cells stained with scFvMTBHsp70
or MTBHsp70 normalized to cells stained without either protein. Data are expressed as means±SEM in arbitrary units. P values were determined
using One-Way ANOVA followed by Turkey’s multiple comparison tests. *,p<0.05; **,p< 0.01;ns, non-significant. E, scFvMTBHsp70 binds with
peritoneal mesothelial cells at a low level compared to ovarian cancer and mesothelioma cells. Binding of the fusion protein is at very low or
undetectable levels on PBLs and splenocytes. Thick line, with incubation of scFvMTBHsp70; solid, without incubation of scFvMTBHsp70. Data are
representative of three independent experiments.
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40L mesothelioma cells through the interaction of scFv
with MSLN on the surface of tumor cells
Binding of scFvMTBHsp70 or MTBHsp70 to BR5FVB1
ovarian cancer cells or 40L mesothelioma cells, as deter-
mined by flow cytometry, is shown in Figure 1C and D.
Binding of scFvMTBHsp70 to MSLN-expressing tumor
cells was almost completely inhibited by preincubation
of scFvMTBHsp70 with recombinant human MSLN. Al-
though MTBHsp70 also binds to these MSLN-expressing
tumor cells, the level of binding is not significantly different
from background (p=0.187 for BR5FVB1 cells, and
p=0.086 for 40L cells). Furthermore, the binding of
MTBHsp70 to cancer cells cannot be blocked by recombin-
ant MSLN. These data support the view that binding of
scFvMTBHsp70 to these tumor cells occurred via the inter-
action of the scFv portion of the fusion protein with MSLN
on the surface of tumor cells. Binding of these proteins with
40L mesothelioma cells was further compared using fluor-
escence microscopy. scFvMTBHsp70 shows significantly
stronger binding intensity as compared to MTBHsp70
(Additional file 1: Figure S1A and B). In order to determine
if scFvMTBHsp70 also binds to normal tissue in addition
to tumor cells, we incubated the fusion protein with periph-
eral blood leukocytes (PBLs), splenocytes, or peritoneal
mesothelial cells from healthy FVB/NJ mice, and stained
the cells using the same method as was used for staining
tumor cells. As shown in Figure 1E, scFvMTBHsp70 binds
with peritoneal mesothelial cells at a low level compared to
ovarian cancer and mesothelioma cells. Binding of the
fusion protein is at very low or undetectable levels on PBLs
and splenocytes. Since scFvMTBHsp70 may potentially tar-
get peritoneal mesothelial cells, we also explored whether it
could induce inflammation in peritoneal mesothelial tis-
sues. We injected naïve mice with saline, scFvMTBHsp70,
or MTBHsp70 plus P4 scFv at the same doses as those used
for tumor therapy described in Method, sacrificed the mice
7 days post final treatments, and examined haematoxylin
and eosin (H&E) stained sections prepared from abdominal
and intestinal peritoneum. Light microscopic examination
revealed no evidence of inflammation and no infiltration of
inflammatory cells such as macrophages or granulocytic
cells around the mesothelial cells lining the abdominal
and intestinal peritoneum of the actively treated or control
animals. Representative microscopic images are shown
in Additional file 2: Figure S2.
scFvMTBHsp70 significantly prolongs ascites-free survival
and overall survival in ovarian cancer- or mesothelioma-
bearing mice
To determine whether scFvMTBHsp70 can prolong
survival in tumor-bearing mice, we first evaluated the
protein in a syngeneic mouse model of papillary ovarian
cancer using immune-competent FVB/NJ mice. As shown
in Figure 2A, scFvMTBHsp70 prolonged both ascites-
free and overall survival time compared with saline or
the equimolar mixture of MTBHsp70 plus P4 scFv. To
further support the efficacy of this fusion protein in
prolonging survival in MSLN-expressing tumor-bearing
mice, we evaluated this protein in a second syngeneic
mouse model of mesothelioma using immune-competent
C57BL/6 mice. Animals treated with scFvMTBHsp70
showed significantly prolonged ascites-free and overall
survival time compared with saline- or MTBHsp70 plus
P4 scFv- treated mice (Figure 2B).
scFvMTBHsp70 enhances anti-tumor CD8
+ T-cell
responses in ovarian tumor-bearing mice
To investigate whether the anti-tumor effects of scFv-
MTBHsp70 was associated with anti-tumor effector
CD8
+ T-cell responses, we re-stimulated splenocytes
from ovarian tumor-bearing FVB mice that received dif-
ferent treatments with the CD8
+ T-cell Her2/neu epi-
tope or MSLN Ld1 as a negative control, ex vivo, and
analyzed the cells for production of IFNγ and Granzyme
B using flow cytometry. We previously showed that
Her2/neu is expressed by BR5FVB1 cells [25]. Ld1 is an
in-house designed H2
d-restricted MSLN peptide that
did not induce ovarian cancer specific T-cell response in
H-2
q FVB mice. We demonstrated significantly greater
anti-Her2/neu CD8
+ T-cell responses in splenocytes
from scFvMTBHsp70-treated mice compared to mice
treated with saline or a simple mixture of MTBHsp70
plus P4 scFv, as measured by IFNγ and Granzyme B
production by CD8
+ T cells (Figure 3A and B). This in-
dicates that scFvMTBHsp70 enhances anti-tumor spe-
cific CD8
+ T-cell responses in ovarian tumor-bearing
mice. However, no significant difference was seen in
the number of tumor-infiltrating CD8
+ T cells and no
tumor-infiltrating Foxp3
+ T cells were seen in tumors
from mice in different treatment groups, indicating that
scFvMTBHsp70 may improve effector cell function
rather than the number of intratumoral CD8
+ T cells
(Additional file 3: Figure S3A and B).
scFvMTBHsp70 is able to prime an adaptive, tumor-specific
immune response that has an absolute requirement for
tumor-specific CD8
+ Tc e l l s
To determine whether CD8
+ T cells play a major role
in the protective anti-tumor effects observed in mice
treated with scFvMTBHsp70, we conducted in vivo
CD8
+ T-cell depletion experiments using monoclonal
antibodies. The absence of circulating CD8
+ cells in per-
ipheral blood, following depletion, was confirmed by
flow cytometry (Additional file 4: Figure S4A and B). As
shown in Figure 3C, CD8
+ T-cell depletion significantly
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scFvMTBHsp70-treated BR5FVB1 tumor-bearing ani-
mals compared to non-depleted, actively-treated ani-
mals. Following CD8
+ T-cell depletion, scFvMTBHsp70
treatment did not delay onset of disease (clinically evi-
dent ascites), compared to saline treatment. Therefore,
our data suggest that the priming of an adaptive, tumor-
specific immune response by scFvMTBHsp70 treatment
is chiefly mediated by tumor-specific CD8
+ T cells.
scFvMTBHsp70 stimulates maturation of murine bone
marrow-derived dendritic cells
In order to investigate immunological mechanisms in-
volved in the scFvMTBHsp70-enhanced anti-tumor im-
mune response, we first examined if the scFvMTBHsp70
or MTBHsp70 proteins used in our study could stimu-
late maturation of bone marrow-derived dendritic cells
(BMDCs) as shown in previous studies [16,17]. We stim-
ulated CD11c
+ BMDCs with 2 μg/ml of scFvMTBHsp70
or an equimolar amount of MTBHsp70 (1.3 μg/ml).
1 μg/ml lipopolysaccharide (LPS) was used as po-
sitive control. To determine whether the BMDC
maturation was attributable to LPS contamination of
the recombinant proteins used in this study, we also
incubated BMDCs with 0.1 ng/ml LPS, which was the
equivalent amount of endotoxin found in 2 μg/ml scFv-
MTBHsp70. After a 24 h-incubation, both scFvMTBHsp70
and MTBHsp70 induced DC maturation indicated by an in-
crease in the expression of CD40, CD80, CD86 and MHC
class II molecules in comparison to the control cultures in
medium. The increased expression of these DC maturation
markers were comparable to those on cells stimulated
with 1 μg/ml LPS. The contamination control showed that
addition of 0.1 ng/ml LPS did not replicate the effects of
scFvMTBHsp70 or MTBHsp70, allowing us to discriminate
the scFvMTBHsp70- or MTBHsp70-specific effects from
effects of LPS (Figure 4A and B).
The scFvMTBHsp70 fusion protein increases tumor
antigen presentation and cross-presentation by DC
in vitro
In the current study, we demonstrated that splenic
CD8
+ T cells from scFvMTBHsp70-treated tumor-bearing
mice could produce cytokines upon specific tumor antigen
Figure 2 A and B, Kaplan-Meier survival curves of tumor-bearing mice following treatment with scFvMTBHsp70, control proteins or
normal saline. A, In a syngeneic mouse model of papillary ovarian cancer in immune-competent FVB/NJ mice, scFvMTBHsp70 prolonged ascites-
free survival time compared with saline (n= 10 per group, representative of two independent experiments; median survival (Med. sur.)=47 days
vs. 37.5 days), or the mixture of MTBHsp70 plus P4 scFv (Med. sur. = 39 days). scFvMTBHsp70 also prolonged overall survival time in the mice
compared with saline (Med. sur. = 51.5 days vs. 43 days), or the mixture of MTBHsp70 plus P4 scFv (Med. sur. = 43 days). B, In a syngeneic mouse
model of mesothelioma in immune-competent C57BL/6 mice, the fusion protein prolonged ascites-free survival time compared with saline-
treated mice (n= 20 per group, pooled from two independent experiments; Med. sur. = 28 days vs. 26 days), or the mixture of MTBHsp70 plus P4
scFv (Med. sur. = 27 days). The fusion protein also prolonged overall survival time compared with saline (Med. sur. = 36 days vs. 31 days). P values
were determined using the log-rank test. *,p<0.05; **,p<0.01; ***,p <0.001.
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+ T-cell functions in tumor-bearing mice following different treatments. A, Splenocytes harvested from
mice treated with scFvMTBHsp70 fusion protein, equimolar mixture of MTBHsp70 plus P4 scFv, or saline (n = 10 per group) were re-stimulated
with Her2/neu peptide or MSLN Ld1 peptide. Results are reported as the difference between nonstimulated (media alone) and stimulated cells
and expressed as the frequency of parent CD3
+CD8
+ cells. P values were determined using One-Way ANOVA followed by Dunnett’s multiple
comparison tests. B, Representative flow data are presented. C, In vivo CD8
+ T-cell depletion study. FVB/NJ mice were injected i.p. with anti-CD8
mAb or an isotype-matched irrelevant rat IgG2a, and were treated with scFvMTBHsp70 or saline as described in the methods. CD8
+ T-cell depletion
significantly and negatively impacted ascites-free survival in the scFvMTBHsp70 treated BR5FVB1 tumor-bearing animals compared to non depleted
actively treated (n = 10 per group, representative of two independent experiments; Med. sur. = 32.5 days vs. 48 days) animals. After CD8
+ Tc e l l s
depletion, scFvMTBHsp70 treatment did not delay onset of disease (clinically evident ascites), compared with saline (Med. sur. = 32.5 days vs. 31.5 days;
p = 0.5938). P values were determined using log-rank test. *,p< 0.05; **,p < 0.01, ***,p < 0.001.
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tumor therapeutic efficacy in vivo. To determine whether
scFvMTBHsp70 promotes tumor specific T-cell responses
by enhancing antigen presentation and cross-presentation
by antigen presenting cells, we co-cultured BR5FVB1
tumor cell-primed T cells with DCs that had been pulsed
with BR5FVB1 tumor cells in the presence of scFv-
MTBHsp70, MTBHsp70, or PBS. The scFvMTBHsp70/
tumor cell-pulsed DCs induced significantly higher
production of IFN-γ and Granzyme B from both CD4
+
and CD8
+ tumor cell-primed T cells as compared with
MTBHsp70 or PBS, indicating that scFvMTBHsp70 en-
hances tumor antigen presentation and cross-presentation
by DCs (Figure 4C and D).
scFvMTBHsp70 enhances tumor cell immunogenicity
in vivo
Having demonstrated in vitro that scFvMTBHsp70 en-
hances tumor antigen presentation and cross-presentation
by DCs, we next explored whether scFvMTBHsp70 en-
hances tumor antigen presentation and cross-presentation
by DCs and consequently enhances tumor cell immuno-
genicity in vivo. It has been demonstrated that the high
density of DCs at dermal sites facilitates the capture of
tumor antigens and that local inflammation induces DC
maturation and migration into draining lymph nodes,
where they present antigens to naïve T cells, generating a
tumor specific immune response [26]. We primed FVB
mice with an intradermal (i.d.) injection of mitomycin
C-treated BR5FVB1 tumor cells, followed by a booster i.d.
injection of BR5FVB1 tumor cells with or without
scFvMTBHsp70 or MTBhsp70. After 20 days, we dissoci-
ated skin-draining lymph nodes and re-stimulated lymph
node lymphocytes with Her2/neu peptides, mitomycin C-
treated BR5FVB1 tumor cells, or BR5FVB1 tumor cell lys-
ate, and performed flow cytometric analysis for the pres-
ence of Granzyme B-generating CD4
+ and CD8
+ Tc e l l s .
As shown in Figure 4E, we demonstrated that Granzyme
B-generating CD4
+ and CD8
+ T cells were significantly
enhanced in mice that were immunized with scFv-
MTBHsp70-bound tumor cells, as compared to those in
the mice immunized with tumor cells alone, MTBHsp70-
bound tumor cells, or saline.
Discussion
We have developed a novel protein-based immunother-
apy consisting of a fusion of an anti-MSLN scFv of hu-
man origin and recombinant mycobacterial heat shock
protein 70 that has the ability to adjuvant significant
T-cell responses against specific tumor antigens. P4 scFv
directed against MSLN, a surface antigen overexpressed
on several types of tumor cells, is used as a means of tar-
geting the immunotherapeutic agent. We have demon-
strated that this bifunctional fusion protein effectively
binds BR5FVB1 ovarian cancer cells or 40L mesotheli-
oma cells through the interaction of scFv with MSLN on
the surface of tumor cells. We found that the fusion pro-
tein significantly prolonged survival time in syngeneic
mouse models of papillary ovarian cancer and malignant
mesothelioma. Treatment with the fusion protein in-
duced significant tumor-specific CD8
+ T-cell immune
responses in the splenocytes of ovarian tumor-bearing
mice. Furthermore, in vivo CD8
+ T-cell depletion studies
demonstrated that this protective antitumor effect is
mainly mediated by tumor-specific CD8
+ T cells. Treat-
ment using a mixture of MTBHsp70 plus P4 scFv for
ovarian tumor or malignant mesothelioma-bearing mice
did not increase survival or enhance tumor-specific im-
mune responses, suggesting that only through fusion of
the two elements is the immune system effectively acti-
vated. We also demonstrated that this approach does
not induce inflammation in the abdominal or intestinal
mesothelial tissues as a result of a bystander interaction
with MSLN on normal mesothelial cells.
Several properties of MTBHsp70 appear in this study
to contribute to the generation of tumor-specific CD4
+
and CD8
+ T-cell immune responses. First, it induces
maturation of DCs. Although several previous studies
(See figure on previous page.)
Figure 4 scFvMTBHsp70 induces DC maturation and promotes antigen presentation and cross-presentation. A, CD11c
+ BMDCs isolated
form FVB/NJ mice were incubated for 24 h with 2 μg/ml scFvMTBHsp70, 1.3 μg/ml MTBHsp70, 1 μg/ml LPS as positive control, or 0.1 ng/ml LPS
as contamination control (thick lines), or medium only (solid), stained for CD11c, CD40, CD80, CD86, and MHC II, and analyzed by flow cytometry.
Histograms were gated on CD11c
+ DCs. Data are representative of three independent experiments in duplicate wells. B, Median fluorescence
intensity (MFI) of LPS- or protein-stimulated BMDCs normalized to MFI of BMDCs maintained in medium. Data are expressed as means±SEM
in arbitrary units. P values were determined using One-Way ANOVA followed by Dunnett’s multiple comparison tests. C, BMDCs cultured from
FVB/NJ mice were pulsed with BR5FVB1 cells alone (Column a), or BR5FVB1 cells pre-complexed with MTBHsp70 (Column b) or scFvMTBHsp70
(Column c), and then incubated with BR5FVB1 tumor cell-primed T cells. Intracellular granzyme B and IFNγ expressions in CD3
+CD4
+ and
CD3
+CD8
+ T cells were analyzed by flow cytometry. Data from three independent experiments in duplicate wells are pooled and analyzed using
One-Way ANOVA followed by Turkey’s multiple comparison tests. Data are presented as mean±SEM. D, Representative flow data are presented.
E, scFvMTBHsp70 enhanced tumor cell immunogenicity in vivo. Results are reported as the difference between nonstimulated (media alone)
and stimulated cells and expressed as the frequency of parent CD3
+CD4
+ or CD3
+CD8
+ cells. P values were determined using One-Way ANOVA
followed by Turkey’s multiple comparison tests. *,p< 0.05; **,p< 0.01; ***,p<0.001; ****,p<0.0001.
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erties only when contaminated with LPS [27,28], other
studies have decisively demonstrated that MTBHsp70
alone while not LPS promotes DC maturation and innate
immune responses [16,17,29]. In our study, we used a fu-
sion protein generated from a mammalian cell expression
system, ensuring a minimal amount of LPS contamination.
We also incubated DCs with the same amount of LPS as
that found in the fusion protein and failed to replicate the
effects observed with the fusion protein, supporting the
view that maturation of DCs can be attributed to the fu-
sion protein rather than LPS. Secondly, MTBHsp70 is
capable of delivering epitopes for enhanced processing
and MHC-I presentation by DCs to naïve CD8
+ T cells,
a process known as cross-presentation [30]. Mycobacterial
Hsp70 fusion proteins have been shown to elicit both
CD4+ and CD8
+ T-cell responses although priming of
CD8
+ T cells does not appear to require CD4
+ T cells
[31,32]. We demonstrated in this study that the MSLN-
targeted fusion protein elicited significant tumor-specific
CD8
+ T-cell immune responses in ovarian cancer-bearing
mice, and this adaptive antitumor response has an abso-
lute requirement for tumor-specific CD8
+ T cells. Al-
though at the dosing schedule used in these studies,
tumor-specific T-cell responses did not eventually lead to
rejection of the established tumors, they significantly
prolonged survival time in tumor-bearing mice.
DCs are believed to play a pivotal role in the initiation
and programming of tumor-specific T-cell responses, and
are becoming an essential target in efforts to generate
therapeutic immunity against cancer [33]. Two main ap-
proaches are currently under consideration for providing
DCs with tumor-specific antigens. One approach is to cul-
ture patient-derived DCs ex vivo with an adjuvant that in-
duces DC maturation in the presence of tumor specific
antigens, followed by adoptive transfer into the patient
[33]. This approach is fraught with technical and practical
difficulties such as selection of a suitable antigenic target,
inappropriate maturation state of selected DCs, and the
difficulty of generating a sufficient number of DCs ex vivo.
In addition, a number of investigators have recently re-
ported that ex vivo-derived DC vaccines have an insignifi-
cant role in the direct priming of Tcells in vivo [33-35].
An alternative approach to generate tumor-specific anti-
gen bearing DCs is to induce them to take up tumor-
specific antigens in vivo. It has been shown that in vivo
specific targeting of tumor antigens to DCs improves
the induction of antigen-specific CD4
+ and CD8
+ T-cell
immunity. In these studies, an agonistic anti-CD40
monoclonal antibody was used to mature DCs and
eliminate antigen-specific tolerance [36-39]. MTBHsp70
has also been shown to stimulate inflammation and DC
maturation via an interaction with CD40 receptors on
both DCs and monocytes, thus acting as an alternative
ligand to CD40L [29,40]. In our study, we showed the fu-
sion protein up-regulates surface expression of phenotypic
markers of DC maturation. Interestingly, in addition to
CD80, CD86, and MHC class II molecules, the expression
of CD40 is also enhanced, indicating a possible positive
feedback loop involving CD40 signaling components.
Beyond promoting DC maturation, the scFvMTBHsp70
fusion protein also targets tumor cells towards the ma-
tured DCs. We propose that binding of the fusion protein
with both tumor cells and DCs improves phagocytosis of
parts of tumor cells by DCs, and therefore any tumor anti-
gen can be processed and loaded on both MHC class II
and MHC class I molecules, and presented to CD4
+ and
CD8
+ T cells. This could explain the observed augmenta-
tion of tumor antigen presentation and cross-presentation
brought about by the fusion protein in vitro. This may also
explain the observed increased anti-Her2/neu CD8
+ T-cell
responses in the scFvMTBHsp70-treated ovarian tumor
bearing mice, although Her2/neu is not directly targeted.
We recapitulated these in vitro findings in an in vivo
tumor cell immunogenicity study. We used the fusion
protein to activate and mature DCs in the skin such as
Langerhans cells. These DCs then captured tumor cells or
tumor cell fragments through the connection established
by the fusion protein, and migrated to the draining lymph-
oid organs where they presented tumor antigens to naïve
T cells. T cells recovered from the draining lymph node
showed significantly enhanced responses to stimulation
with a range of tumor antigens.
Conclusion
Our study provides preclinical evidence that supports a
protein-based immunotherapy that induces anti-tumor
immune responses, which normally require dendritic cell-
based approaches. The MSLN-targeted MTBHsp70 fusion
protein binds MSLN on tumor cells, recruits and activates
APCs including DCs, loads DCs in vivo with the broadest
profile of naturally processed tumor antigens, promotes
tumor antigen presentation and cross-presentation, and
enhances tumor specific CD4
+ and CD8
+ T-cell responses
(Figure 5). Our study supports the continued exploration
of this novel fusion protein alone or in combination
with immune checkpoint inhibitors, following conven-
tional surgical reduction and chemotherapy for MSLN-
expressing cancers. This new approach could significantly
increase time to recurrence and survival in humans with
ovarian cancer and mesothelioma where effective second
line treatment options are very limited.
Methods
Production of proteins
The plasmid pQE30-MTBhsp70 that encodes full length
MTBHsp70 was a generous gift from Dr. Peter Sveshnikov
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R2-scFv that encodes an scFv fragment specific to MSLN
and the recombinant P4 scFv protein [13], generated and
purified from yeast, were generous gifts from Dr.
Nathalie Scholler (Penn Ovarian Cancer Research
Center, University of Pennsylvania). The DNA fragment
corresponding to a 15 amino acid linker (GGGGS
GGGGSGGGGS) was connected to the scFv at its
C-terminal using an overlap PCR approach. The PCR
product scFv-linker was subcloned into pQE30-
MTBhsp70 at the N-terminal of MTBhsp70. The DNA
fragment for scFvMTBhsp70 was PCR amplified and
cloned into pPMY5 (Promab), downstream of a human
IgG1 Fc domain and separated from the Fc region by
t h es i g n a lc l e a v a g es e q u e n c ef o rT o b a c c oE t c hV i r u s
protease (TEV enzyme). scFvMTBHsp70, the MSLN-
targeted fusion protein, was generated from HEK293
cells and purified using Protein G resin (Pierce). The Fc
region of the Protein G eluted protein was then cleaved
from the fusion protein by TEV enzyme (Promab)
digestion. MTBHsp70 was generated using the same
expression system. The production and purification
of these two proteins was accomplished by Promab
Biotechnologies, Inc. at Richmond CA. After purifica-
tion and hIgG-Fc tag removal, the integrity of scFv-
MTBHsp70 and MTBHsp70 were determined by
SDS-PAGE, followed by staining with RAPIDstain
(G-Bioscience). Endotoxin contamination levels in
scFvMTBHsp70 and MTBHsp70 were determined by
Limulus Amebocyte Lysate Assay (LAL-assay, Cambrex).
Cells
The BR5FVB1 ovarian cancer cells, a kind gift from
Dr. Orsulic in Women’s Cancer Research Institute at
Cedars-Sinai Medical Center [41], or 40L mesothelioma
cells, a kind gift from Dr. Kane in Department of
Pathology and Laboratory Medicine at Brown University
[42], were maintained at 37°C in DMEM with 2 mmol/L
L-glutamine, 10 units/ml penicillin, 10 μg/ml strepto-
mycin, and 10% fetal bovine serum in humidified
atmosphere with 5% CO2. Cells were cultured until
80% confluent, and harvested with enzyme-free cell-
dissociation buffer (Gibco) for in vitro tumor cell bind-
ing assays and cross-presentation studies, or harvested
with Trypsin EDTA (Mediatech) for animal injec-
tions. Mouse PBLs were obtained from FVB mice via
tail vein bleeds, after lysis of erythrocytes using M-
lyse buffer (R&D systems). Small pieces of parietal
peritoneal membrane were taken from the mice and
digested in enzyme-free cell-dissociation buffer to obtain
mouse peritoneal mesothelial cells. To test whether
scFvMTBHsp70 or MTBHsp70 binds to the MSLN-
expressing tumor cells, or non-cancerous cells, we incu-
bated BR5FVB1 ovarian tumor cells, 40L mesothelioma
cells, or normal cells from FVB mice including PBLs,
splenocytes, and peritoneal mesothelial cells with 40 μg/
ml scFvMTBHsp70 or 26 μg/ml MTBHsp70, followed by
anti-MTBHsp70 (IgG2a) (Biodesign International), bio-
tinylated anti-IgG2a (BD Bioscience), and Streptavidin-
APC (BioLegend), and then analyzed the tumor cells
by flow cytometry. As controls, cells were incubated with
Figure 5 A schematic model showing that the scFvMTBHsp70 fusion protein binds with MSLN on tumor cells and activates antigen
presenting cells (APCs), thus promoting uptake of tumor cells or tumor cell fragments, and promoting tumor antigen presentation
and cross-presentation as well as adjuvanting tumor specific CD4
+ and CD8
+ T-cell responses.
Yuan et al. Journal of Hematology & Oncology 2014, 7:15 Page 10 of 14
http://www.jhoonline.org/content/7/1/15the reagents described above except scFvMTBHsp70 or
MTBHsp70. To confirm that scFv portion of the fusion pro-
tein binds to MSLN on the surface of tumor cells,
scFvMTBHsp70 or MTBHsp70 was preincubated with 12
μg/ml of recombinant human MSLN (R&D Systems) for 30
min before adding to the cells. For fluorescence microscopy,
cells were cultured on coverslips until 50% confluent, stained
with 10 μg/ml scFvMTBHsp70 or 6.5 μg/ml MTBHsp70,
followed by mouse anti-MTBHsp70 (1:500 dilution), and
Donkey anti-mouse Alexa Fluor 594 (Invitrogen, 1:500 dilu-
tion). Cells were observed using a Nikon Eclipse TiE fluores-
cence microscope. In some experiments, tumor cells were
treated with 20 μg/ml mitomycin C at a concentration of
5×1 0
6/ml for 1 h in a 37°C water bath, and washed with
complete medium at least 3 times before use.
Animal models and tumor treatment
Ovarian cancer was established by i.p. injection of synge-
neic cancer cells BR5FVB1 (10
7 cells per mouse) into
6-week-old female FVB/NJ mice as previously described
[25]. All mice were purchased from Jackson laboratories.
Intraperitoneal mesotheliomas we r ee s t a b l i s h e db yi . p .i n j e c -
tion of syngeneic 40L cells (2 ×10
6 per mouse) into 6-week-
old male C57BL/6 mice as previously described [42]. Mice
with ovarian tumors were treated 7 days after BR5FVB1
tumor cell inoculation with i.p. injections of scFvMTBHsp70
(2 μg per mouse), normal saline, or an equimolar mixture of
MTBHsp70 plus P4 scFv. This was followed by 3 further
treatments at 4-day intervals. In the mesothelioma model,
C57BL/6 mice were treated 5 days after 40L tumor cell in-
oculation, and injected i.p. with scFvMTBHsp70 (2 μgp e r
mouse), normal saline, or an equimolar mixture of
MTBHsp70 plus P4 scFv. Three subsequent doses were ad-
ministered at 3-day intervals, thereafter. For survival stud-
ies, we observed the mice daily 3 weeks after inoculation of
BR5FVB1 cells or 1 week after inoculation of 40L cells.
Tumor generations were consistently first evident via ab-
dominal distension secondary to malignant ascites, and
tumor-bearing mice were euthanized at the endpoint when
there were signs of distress, including fur ruffling, rapid
respiratory rate, hunched posture, reduced activity, and
progressive ascites formation as previously described [25].
For the investigation of anti-tumor T-cell responses, all
ovarian tumor-bearing mice were sacrificed 7 days after
the final scheduled treatment. All studies were performed
in a manner that was blinded to the observer under proto-
cols that were approved by the Massachusetts General
Hospital Subcommittee on Research Animal Care (SRAC).
Treatment of naïve mice with experimental or control
protein
6-week-old male C57BL/6 mice were injected i.p. with
scFvMTBHsp70 (2 μg per mouse), normal saline, or an
equimolar mixture of MTBHsp70 plus P4 scFv. Three
subsequent doses were administered at 3-day intervals
thereafter. Seven days post the administration of the
final treatment, mice were sacrificed and abdominal wall
and intestine were retrieved for histopathological studies
of mesothelial tissues.
Ex vivo assessment of tumor specific T-cell functions
Single cell suspensions were prepared from spleens. Cells
were plated in round-bottomed 96-well plates, pulsed with
a validated CD8
+ T-cell Her2/neu peptide (PDSLRDLSVF,
1 μg/ml; EZBiolab) [25,43], an in-house designed H2
d-re-
stricted MSLN Ld1 peptide (IPLSYLCDF, 1 μg/ml; EZBio-
lab) that did not induce ovarian cancer specific T-cell
response in H-2
q FVB mice, or medium alone for 72 hours
when Golgi Plug (BD Bioscience) was added for the last
5 hours as previously described [44], and then stained
with fluorophore-conjugated anti-CD3, anti-CD4, anti-
CD8, anti-IFNγ (BD Pharmingen), and anti-Granzyme B
(eBioscience) antibodies. Cells were then analyzed on a
LSRII 4 laser (BD Biosciences).
Depletion of CD8
+ T cells in vivo
FVB/NJ mice were injected i.p. with 200 μg of anti-CD8
monoclonal antibody (mAb)(53–6.72, Bio X Cell) or an
isotype-matched irrelevant rat IgG2a (2A3, Bio X Cell) 2
days before, 1 day before and 1 day after i.p. inoculation
with BR5FVB1 ovarian tumor cells. Depletion was con-
tinued once every week until 29 days after tumor inocu-
lation. The mice were treated with scFvMTBHsp70 or
saline as described above. All the mice were bled from
the tail vein and the depletion of CD8
+ cells was exam-
ined by flow cytometry analysis of peripheral blood cells
stained with fluorophore-conjugated anti-CD8 on days 7
and 28 after tumor inoculation.
Generation and purification of bone marrow-derived
DCs (BMDCs)
CD11c
+ DCs were generated from bone marrow cells of
FVB/NJ mice as described [45-47], with minor modifica-
tions. Briefly, erythrocyte-depleted mouse bone marrow cells
from flushed marrow cavities were cultured in complete
RPMI 1640 with 10 ng/ml GM-CSF and 1 ng/ml IL-4 at 1 ×
10
6 cells/ml. Medium was changed on day 3. On day 7, DCs
were harvested by gentle pipetting and purified with mag-
netic microbeads conjugated to a monoclonal antibody
against CD11c (MiltenyiBiotec) as described [46,48], accord-
ing to the manufacturer’s recommended protocol.
In vitro activation of BMDCs
CD11c
+ BMDCs were plated in a 24-well plate at a
density of 2 × 10
6 cells/ml and incubated with 2 μg/ml
scFvMTBHsp70 (105 kDa), 1.3 μg/ml MTBHsp70
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3 EU/ml endotoxin
(InvivoGen, San Diego, CA), or 0.1 ng/ml (0.1 EU/ml) LPS
equivalent to endotoxin found in 2 μg/ml of proteins
(since LPS level is less than 50 EU per mg of protein)
for 24 h at 37°C in humidified atmosphere with 5% CO2.
Cells were then placed on ice, collected by vigorous
pipetting, washed and stained with the following fluoro-
phore-conjugated antibodies: anti-CD11c and anti-CD40
(eBioscience), anti-CD80 (BD Horizon), anti-CD86 and
anti-MHC class II (I-A
q) (BD Pharmingen). Afterwards, the
cells were analyzed on an LSRII 4 laser (BD Biosciences).
In vitro tumor antigen presentation assay
BR5FVB1 cells were harvested and treated with mitomy-
cin C, and plated in a 96-well round-bottomed plate
with 20 μg/ml scFvMTBHsp70 or 13 μg/ml MTBHsp70.
After pre-incubation at 4°C for 1 h, CD11c
+ BMDCs
(ratio of tumor cells: DCs = 3: 1) were added to the wells
and the plate was incubated at 37°C for 24 h. For gener-
ation of BR5FVB1 cell-primed T cells, we inoculated
FVB/NJ mice by i.p. injection with 10
7mitomycin
C-treated BR5FVB1 cells and sacrificed the mice 60
days after the immunization according to the approved
animal protocol. Splenocytes were then harvested, and
T cells were isolated using the Pan T-Cell Isolation Kit II
(MiltenyiBiotec). BR5FVB1 cell-primed T cells were then
added to the wells at a DC/T-cell ratio of 1:20. After a
24-hour co-culture of BR5FVB1 cell-pulsed DCs with
BR5FVB1 cell-primed T cells, the cells were harvested,
washed and resuspended in PBS with 5% FBS, stained
for CD3, CD4, CD8 and IFNγ, and analyzed on a LSRII
4 laser (BD Biosciences).
In vivo immunization with mitomycin C-treated ovarian
tumor cells
BR5FVB1 ovarian tumor cells were harvested with
enzyme-free cell-dissociation buffer and treated with
mitomycin C as described above. Cells were then pre-
incubated with scFvMTBHsp70 (10 μg/10
6 cells), MTB-
Hsp70 (6.5 μg/10
6 cells), or PBS alone at 4°C for 1 h.
6-week-old FVB mice were shaved and depilated on
both left and right flanks, and then injected i.d. with
50 μlo fP B S ,o r1×1 0
6 tumor cells in 50 μl of PBS with
or without a pre-incubation with scFvMTBHsp70 or
MTBHsp70 at both flanks.
Histopathology
Abdominal walls and intestines from mice were fixed for
at least 24 h in PBS-buffered 10% formalin. Tissues were
routinely embedded in paraffin. 5 μm thick sections
were stained routinely with H&E. For staining tumor-
infiltrating T cells, mice were perfused with 4% parafor-
maldehyde (PFA) in PBS, and tumor nodules were fixed
in 4% PFA/PBS for additional 2 hours, washed and
infiltrated with 30% sucrose/PBS at 4°C. 6 μm thick
frozen sections were stained with rat anti-mouse CD8
(BD Biosciences, 1:100 dilution) or rat anti-mouse Foxp3
(eBioscience, 1:12 dilution), followed by polyclonal rabbit
anti-rat immunoglobulin/HRP (Dako, 1:750 dilution).
Signal was developed with diaminobenzidine (DAB,
Dako). Images were acquired on a Zeiss Axio A1 micro-
scope. All histopathological and immunohistochemical
samples were reviewed and the quantitation of the cellu-
lar infiltrate was performed in a blinded manner to the
observer.
Statistical analysis
Statistical differences between three or more experimen-
tal groups were analyzed using One-Way ANOVA,
followed by Turkey’s multiple comparison tests when
mean of each group is compared with that of every other
group, or followed by Dunnett’s multiple comparison
tests when mean of each group is compared with that of
a control group. Statistical differences between two ex-
perimental groups were analyzed using Student’s t-test.
Survival was analyzed with the Log-rank test. Prism 6.0
software (GraphPad Software) was used for all the statis-
tical analysis.
Additional files
Additional file 1: Figure S1. scFvMTBHsp70 binds to 40L mesothelioma
cells. 40L cells were stained with scFvMTBHsp70 or MTBHsp70, followed by
mouse anti-MTBHsp70, and Donkey anti-mouse Alexa Fluor 594. Cells were
observed using a Nikon Eclipse TiE fluorescence microscope. A, Representa-
tive pictures from three independent experiments. Scale bar, 10 μm. B,
Images were analyzed using the NIS-Elements AR Microscope Imaging
Software. Mean Fluorescence Intensity was analyzed using ImageJ. P values
were determined using One-Way ANOVA followed by Turkey’s multiple
comparison tests. ****,p<0.0001.
Additional file 2: Figure S2. scFvMTBHsp70 or MTBHsp70 plus P4
scFv treatment does not lead to infiltration of inflammatory cells into
abdominal or intestinal mesothelial tissues. Samples of abdominal wall
and intestine were prepared from C57BL/6 mice that had previously
received multiple i.p. injections of scFvMTBHsp70, MTBHsp70 plus P4 scFv
or saline as described in the Methods section. Sections of these tissues
were stained with H&E, and images were acquired on a Zeiss Axio A1
microscope. Representative images from 3 animals per treatment group
are shown. No detectable level of mononuclear cell or granulocyte
infiltrate within mesothelial tissues was seen in any sampled tissues.
Scale bar, 20 μm.
Additional file 3: Figure S3. scFvMTBHsp70 treatment does not affect
numbers of tumor-infiltrating CD8
+ or Foxp3
+ T cells. (A) Representative
images of intratumoral CD8
+ and Foxp3
+ T cells from saline (n= 3),
scFvMTBHsp70 (n= 3), or MTBHsp70 plus P4 scFv (n= 3) -treated mice.
Mouse spleen sections were used as positive controls: CD8
+ and Foxp3
+
T cells are clearly evident in the sections. Scale bar, 20 μm. (B) Numbers
of CD8
+ and Foxp3
+ cells were quantified from 3–5 randomized fields.
Additional file 4: Figure S4. Validation of in vivo depletion of CD8
+
cells in FVB/NJ mice. Mice were injected i.p. with 200 μg of anti-CD8
mAb or an isotype-matched irrelevant rat IgG2a as described in Methods.
All the mice were bled from the tail vein and the depletion of CD8
+
cells was examined by flow cytometry analysis of peripheral blood cells
Yuan et al. Journal of Hematology & Oncology 2014, 7:15 Page 12 of 14
http://www.jhoonline.org/content/7/1/15stained with fluorophore-conjugated anti-CD8 on days 7 and 28 after
tumor inoculation. (A) Representative results of flow analyses on 10 mice
per group and reported as the percentage of CD8
+ cells in lymphocytes.
(B) CD8
+ cells in the mice treated with isotype IgG2a or anti-CD8 mAb
were compared. ***,p< 0.001.
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